Dr. Reddys Laboratories Ltd.

Dr Reddys Laboratories is currently trading at Rs. 2662.90, up by 14.40 points or 0.54% from its previous closing of Rs. 2648.50 on the BSE.

The scrip opened at Rs. 2648.00 and has touched a high and low of Rs. 2662.90 and Rs. 2642.40 respectively. So far 4521 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2662.90 on 15-Jan-2014 and a 52 week low of Rs. 1720.50 on 01-Mar-2013.

Last one week high and low of the scrip stood at Rs. 2662.90 and Rs. 2473.00 respectively. The current market cap of the company is Rs. 45205.71 crore.

The promoters holding in the company stood at 25.52 % while Institutions and Non-Institutions held 41.44 % and 16.16 % respectively.

Galena Biopharma and Dr Reddys Laboratories have entered into strategic partnership for NeuVax in India. NeuVax is the immunodominant nonapeptide derived from the HER2 protein, a target for therapeutic intervention in breast cancer.

Galena will license the commercial rights for NeuVax (nelipepimut-S) to Dr Reddys and the India based pharmaceutical company will also lead the development of NeuVax in Gastric Cancer, significantly expanding the potential addressable patient population. Meanwhile, Galena will receive development and sales milestones, as well as double-digit royalties on net sales.

Galena Biopharma is a biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Dr Reddys Laboratories is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.